Rosen Law Firm Announces uniQure N.V. Securities Fraud Lawsuit

Investors have opportunity to lead class action lawsuit against biopharmaceutical company

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025. The lawsuit alleges that uniQure misrepresented and failed to disclose information about the design and timeline of its Pivotal Study for a leading drug candidate in Huntington's Disease.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures from public companies, especially in the highly regulated biopharmaceutical industry. Investors rely on companies to provide truthful information about their drug development programs and timelines, and any misrepresentations can lead to significant losses.

The details

According to the lawsuit, uniQure is accused of: (1) failing to disclose that the design of its Pivotal Study for its Huntington's Disease drug candidate was not fully approved by the FDA; (2) downplaying the likelihood that it would have to delay its Biologics License Application (BLA) timeline to perform additional studies; and (3) making statements about its business and prospects that lacked a reasonable basis.

  • The class period is from September 24, 2025 to October 31, 2025.
  • Investors have until April 13, 2026 to move the court to serve as lead plaintiff in the class action lawsuit.

The players

uniQure N.V.

A biopharmaceutical company focused on developing gene therapies for rare genetic disorders.

The Rosen Law Firm

A global investor rights law firm that specializes in securities class actions and shareholder derivative litigation.

Got photos? Submit your photos here. ›

What they’re saying

“To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.”

— Phillip Kim, Esq. (Rosen Law Firm)

What’s next

Investors have until April 13, 2026 to move the court to serve as lead plaintiff in the class action lawsuit.

The takeaway

This lawsuit underscores the importance of pharmaceutical companies providing accurate and transparent information to investors about their drug development programs. Investors rely on this information to make informed decisions, and any misrepresentations can lead to significant losses.